One of the primary barriers to treating cancer patients is the development of resistance to the available treatments. This is also the case for the treatment of cancer, such as breast cancer, pancreatic cancer, prostate cancer and ovarian cancer with taxane chemotherapy. Thus, resistance presents a serious clinical issue when using taxanes and identifying drug combinations that synergize with taxanes in taxane resistant cancer would greatly increase the clinical value of taxane treatment.
The results were published in the international peer-reviewed journal “European Journal of Pharmaceutical Sciences”: https://www.sciencedirect.com/science/article/pii/S0928098720301044?via%3Dihub
CSO Jan Stenvang comments
“This is the first publication demonstrating the synergistic effect of combining SCO-101 with chemotherapy. In this publication, we could quantify the synergistic effects and found that the combination of SCO-101 and docetaxel showed an approximately 60% increase in potency compared to docetaxel alone in docetaxel resistant cancer cells. This is an important preclinical demonstration of the concept of SCO-101 mediated re-sensitization of drug-resistant cancer cells that will also guide us towards the optimal dose ratios of SCO-101 and docetaxel in coming clinical studies.Indeed, Scandion Oncology is presently making ready to submit a clinical protocol to the Danish Medicines Agency regarding taxane plus SCO-101 treatment of patients with pancreatic cancer.”
For further information regarding Scandion Oncology, please contact:
Nils Brünner, CEO
Phone: +45 26 14 47 08
This information is information that Scandion Oncology is obliged to publish in accordance to the EU Market Abuse Regulation. The information was provided by the contact person above for publication on March 25, 2020.
Scandion Oncology A/S is a biotechnology company that addresses and tackles one of the greatest challenges in modern oncology – the effective treatment of cancer which contains chemotherapy-resistant cells or which has developed resistance to a previously prescribed cancer-fighting drug. In preclinical in vitro-studies SCO-101 restores chemotherapy sensitivity in resistant cancer cells. Moreover, in animal studies, the company’s leading candidate drug, SCO-101, significantly enhances the efficacy of certain standard cancer treatments when given in combination. Scandion Oncology is now in clinical phase II trials with its lead compound, SCO-101, in patients with chemotherapy-resistant colorectal cancer. In addition to SCO-101 the Company has two other drug candidates, SCO-201 and SCO-301. Scandion Oncology was listed on Spotlight Stock Market, Sweden in November 2018.